Discharge Hemoglobin Level and 30-Day Readmission Rates After Coronary Artery Bypass Surgery

• Published in: Anesthesia and analgesia Vol. 128; no. 2; pp. 342 - 348
• Main Authors: Cho, Brian C, DeMario, Vincent M, Grant, Michael C, Hensley, Nadia B, Brown, Charles H, Hebbar, Sachidanand, Mandal, Kaushik, Whitman, Glenn J, Frank, Steven M
• Format: Journal Article
• Language: English
• Published: United States International Anesthesia Research Society 01.02.2019
• Subjects: Aged; Coronary Artery Bypass - adverse effects; Coronary Artery Bypass - trends; Female; Hemoglobins - metabolism; Humans; Male; Middle Aged; Patient Discharge - trends; Patient Readmission - trends; Postoperative Complications - blood; Postoperative Complications - diagnosis; Retrospective Studies; Risk Factors; Time Factors
• ISSN: 0003-2999; 1526-7598
• DOI: 10.1213/ANE.0000000000003671

BACKGROUND:Restrictive transfusion strategies supported by large randomized trials are resulting in decreased blood utilization in cardiac surgery. What remains to be determined, however, is the impact of lower discharge hemoglobin (Hb) levels on readmission rates. We assessed patients with higher versus lower Hb levels on discharge to compare 30-day readmission rates after coronary artery bypass grafting (CABG). METHODS:We retrospectively evaluated 1552 patients undergoing isolated CABG at our institution from January 2013 to May 2016. We evaluated 2 Hb cohorts“high” (above) and “low” (below) the mean discharge Hb level of 9.4 g/dL, comparing patient characteristics, blood utilization, and clinical outcomes including 30-day readmission rates. We further evaluated the effects of the lowest (<8 g/dL) discharge Hb levels on 30-day readmission rates by dividing the patients into 4 anemia cohorts based on discharge Hb levels“no anemia” (>12 g/dL), “mild anemia” (10–11.9 g/dL), “moderate anemia” (8–9.9 g/dL), and “severe anemia” (<8 g/dL). Risk adjustment accounted for age, sex, Charlson comorbidity index, preoperative comorbidities, revision sternotomy, and patient blood management program implementation. RESULTS:The “high” and “low” groups had similar patient characteristics except for Hb levels (mean discharge Hb was 10.4 ± 0.9 vs 8.5 ± 0.6 g/dL, respectively). Notably, no evidence for a difference in 30-day readmission rates was noted between the “high” (76/746; 10.2%) and “low” (97/806; 12.0%) (P = .25) Hb cohorts. The 4 anemia cohorts had differences in age, revision sternotomy incidence, Hb levels, certain patient comorbidities, and time to readmission. On multivariable analysis, the risk-adjusted odds of readmission in the “low” Hb cohort (odds ratio, 1.16; 95% confidence interval, 0.84–1.61; P = .36) was not significant compared to the “high” Hb cohort. Compared to patients with discharge Hb ≥8 g/dL, patients with Hb <8 g/dL had a higher incidence of readmission (22/129; 17.1% vs 151/1423; 10.6%; P = .036). On multivariable analysis, Hb <8 g/dL on discharge was predictive of readmission (odds ratio, 1.77; 95% confidence interval, 1.05–2.88; P = .03). The most common reason for readmission was volume overload, followed by infection and arrhythmias. CONCLUSIONS:A discharge Hb level below the institution mean for CABG patients does not provide evidence for an association with an increased 30-day readmission rate. In the small number of patients discharged with Hb <8 g/dL, there is a suggestion of increased risk for readmission and larger more controlled studies are needed to verify or refute this finding.